Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Teriflunomide capsule
Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections

First Posted Date: 2016-06-07

Last Posted Date: 2021-10-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 930

Registration Number: NCT02792218

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.

Phase 3

Completed

Conditions: Relapsing Multiple Scelrosis

Interventions: Drug: Ofatumumab subcutaneous injection
Drug: Teriflunomide capsule
Drug: Teriflunomide-matching placebo capsules
Drug: Matching placebo of ofatumumab subcutaneous injections

First Posted Date: 2016-06-07

Last Posted Date: 2021-11-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 955

Registration Number: NCT02792231

Locations: 🇬🇧
Novartis Investigative Site, London, United Kingdom

A Registry of Patients With Moderate to Severe Plaque Psoriasis

Active, not recruiting

Conditions: Psoriasis

Interventions: Drug: Secikinumab

First Posted Date: 2016-05-30

Last Posted Date: 2024-11-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 2384

Registration Number: NCT02786186

Locations: 🇵🇦
Novartis Investigative Site, Panama, Panama

Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome

Phase 2

Completed

Conditions: Primary Sjögren's Syndrome

Interventions: Drug: CDZ173
Drug: Placebo

First Posted Date: 2016-05-18

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02775916

Locations: 🇭🇺
Novartis Investigative Site, Debrecen, Hungary

Study of Efficacy and Safety of Secukinumab in Psoriatic Arthritis and Axial Spondyloarthritis Patients With Active Enthesitis Including One Achilles Tendon Site

Phase 3

Completed

Conditions: Axial Spondyloarthritis
Enthesitis
Psoriatic Arthritis

Interventions: Biological: Secukinumab
Drug: Secukinumab Placebo

First Posted Date: 2016-05-13

Last Posted Date: 2021-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 204

Registration Number: NCT02771210

Locations: 🇬🇧
Novartis Investigative Site, Tyne And Wear, United Kingdom

Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.

Phase 4

Completed

Conditions: Chronic Heart Failure With Reduced Ejection Fraction

Interventions: Drug: LCZ696
Drug: Enalapril
Drug: Placebo matching enalapril
Drug: Placebo matching LCZ696

First Posted Date: 2016-05-11

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 201

Registration Number: NCT02768298

Locations: 🇩🇪
Novartis Investigative Site, Wuppertal, Germany

Efficacy and Safety of LFG316 in Transplant Associated Microangiopathy (TAM) Patients

Phase 2

Terminated

Conditions: Transplant Associated Microangiopathy TAM

Interventions: Drug: LFG316 active drug
Other: Standard of care treatment

First Posted Date: 2016-05-05

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 7

Registration Number: NCT02763644

Locations: 🇩🇪
Novartis Investigative Site, Heidelberg, Germany

Study to Examine the Clinical Efficacy and the Nonsteroidal Anti-inflammatory Drug (NSAID)-Sparing Effect of Secukinumab Over 16 Weeks in Patients With Ankylosing Spondylitis

Phase 4

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Secukinumab (AIN457) 150 mg s.c.
Drug: Placebo - Secukinumab (AIN457) 150 mg s.c.

First Posted Date: 2016-05-05

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 211

Registration Number: NCT02763046

Locations: 🇩🇪
Novartis Investigative Site, Trier, Germany

Determination of Accuracy in Measurement of Total Immunoglobulin E Using a Test Device in Atopic Subjects

Phase 2

Completed

Conditions: Atopic Asthma

Interventions: Procedure: Blood sample
Device: POCT device

First Posted Date: 2016-05-02

Last Posted Date: 2016-11-15

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 193

Registration Number: NCT02758548

Locations: 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom

Panobinostat in Combination With Carfilzomib and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Phase 2

Withdrawn

Conditions: Multiple Myeloma

Interventions: Drug: panobinostat (capsules)
Drug: carfilzomib (infusion)
Drug: dexamethasone (tablets)

First Posted Date: 2016-04-29

Last Posted Date: 2016-11-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02756663

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy